Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: a randomized clinical trial

• Published in: BMC medicine Vol. 22; no. 1; pp. 4 - 17
• Main Authors: Liu, Moqi, Jiao, Xueqiao, Li, Rui, Li, Jialu, Wang, Lu, Wang, Liyan, Wang, Yishu, Lv, Chunmei, Huang, Dan, Wei, Ran, Wang, Liming, Ji, Xunming, Guo, Xiuhai
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.01.2024; BioMed Central; BMC
• Subjects: Acetazolamide; Acidosis; Acute Disease; Acute mountain sickness; Alleles; Altitude; Altitude sickness; Altitude Sickness - diagnosis; Altitude Sickness - prevention & control; Analysis; Antibodies; Blood pressure; Cardiovascular disease; Care and treatment; Clinical trials; Diagnosis; Dosage and administration; Drug dosages; Exposure; Gene polymorphism; Genetic analysis; Genetic aspects; Genetic polymorphisms; Heart rate; High altitude; Humans; Hypoxia; Hypoxia - prevention & control; Illnesses; Inflammation; Intervention; Ischemia; Ischemic Preconditioning; Metabolic acidosis; Mountain sickness; Mountains; Oxygen content; Oxygen saturation; Pathogenesis; PDGF; Physiology, Pathological; Platelet-derived growth factor; Preconditioning; Prevention; Prospective Studies; Pulmonary arteries; Remote ischemic preconditioning; China; Beijing China; Acetazolamide; Acute mountain sickness; Remote ischemic preconditioning; PDGF

We aimed to determine whether and how the combination of acetazolamide and remote ischemic preconditioning (RIPC) reduced the incidence and severity of acute mountain sickness (AMS). This is a prospective, randomized, open-label, blinded endpoint (PROBE) study involving 250 healthy volunteers. Parti...